Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin Pharmaceuticals Inc.

Division of Bristol-Myers Squibb Co.
www.amylin.com

Latest From Amylin Pharmaceuticals Inc.

Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US

US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.

Approvals Metabolic Disorders

Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

Emerging Company Profile: Equillium in-licensed the CD6 inhibitor EQ001 – Biocon's Alzumab (itolizumab), approved in India for psoriasis – and will begin clinical trials for three autoimmune disease indications this year; a Phase Ib/II aGvHD study is under way.

Business Strategies Immune Disorders

US FDA Advertising Citations Remain Rare In 2018

With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.

Advertising, Marketing & Sales Enforcement

Lessons From A Life Sciences Lifetime: An Interview With Sir John Bell

Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.

Leadership Outlook 2019
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bristol-Myers Squibb Co.
  • Senior Management
  • Daniel M Bradbury, Pres. & CEO
    Mark G Foletta, SVP, Fin. & CFO
    Vincent Mihalik, SVP, Sales & Mktg. & Chief Commercial Officer
  • Contact Info
  • Amylin Pharmaceuticals Inc.
    Phone: (858) 552-2200
    9360 Towne Centre Dr.
    Ste. 110
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register